content: <?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
  <submissionType>144</submissionType>
  <filerInfo>
  <filer>
  <filerCredentials>
  <cik>0001103804</cik>
  <ccc>XXXXXXXX</ccc>
  </filerCredentials>
  </filer>
  <liveTestFlag>LIVE</liveTestFlag>
  
  
  
  </filerInfo>
  </headerData>
  <formData>
  <issuerInfo>
  <issuerCik>0001743881</issuerCik>
  <issuerName>BridgeBio Pharma, Inc.</issuerName>
  <secFileNumber>001-38959</secFileNumber>
        <issuerAddress>
  <com:street1>3160 Porter Drive</com:street1>
  <com:street2>Suite 250</com:street2>
  <com:city>Palo Alto</com:city>
  <com:stateOrCountry>CA</com:stateOrCountry>
  <com:zipCode>94304</com:zipCode>
  </issuerAddress>
  <issuerContactPhone>(650) 391-9740</issuerContactPhone>
  <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>VIKING GLOBAL INVESTORS LP</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
  <relationshipsToIssuer>
  <relationshipToIssuer>10% Stockholder</relationshipToIssuer>
  </relationshipsToIssuer>
  </issuerInfo>
  <securitiesInformation>
  <securitiesClassTitle>Common Stock</securitiesClassTitle>
  <brokerOrMarketmakerDetails>
  <name>Citigroup</name>
  <address>
  <com:street1>388 Greenwich Street</com:street1>
  <com:city>New York</com:city>
  <com:stateOrCountry>NY</com:stateOrCountry>
  <com:zipCode>10013</com:zipCode>
  </address>
  </brokerOrMarketmakerDetails>
  <noOfUnitsSold>3065616</noOfUnitsSold>
  <aggregateMarketValue>106989998.4</aggregateMarketValue>
  <noOfUnitsOutstanding>188989802</noOfUnitsOutstanding>
  <approxSaleDate>01/31/2025</approxSaleDate>
  <securitiesExchangeName>NASDAQ</securitiesExchangeName>
  </securitiesInformation>
  <securitiesToBeSold>
  <securitiesClassTitle>Common Stock</securitiesClassTitle>
  <acquiredDate>06/27/2019</acquiredDate>
  <natureOfAcquisitionTransaction>Purchases in Issuer's IPO</natureOfAcquisitionTransaction>
  <nameOfPersonfromWhomAcquired>Underwriter</nameOfPersonfromWhomAcquired>
  <isGiftTransaction>N</isGiftTransaction>
  <amountOfSecuritiesAcquired>625937</amountOfSecuritiesAcquired>
  <paymentDate>07/01/2019</paymentDate>
  <natureOfPayment>Cash</natureOfPayment>
  </securitiesToBeSold>
  <securitiesToBeSold>
  <securitiesClassTitle>Common Stock</securitiesClassTitle>
  <acquiredDate>06/27/2019</acquiredDate>
  <natureOfAcquisitionTransaction>Conversion of Series C Preferred Units in Issuer's IPO</natureOfAcquisitionTransaction>
  <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
  <isGiftTransaction>N</isGiftTransaction>
  <amountOfSecuritiesAcquired>479280</amountOfSecuritiesAcquired>
  <paymentDate>08/15/2017</paymentDate>
  <natureOfPayment>Cash</natureOfPayment>
  </securitiesToBeSold>
  <securitiesToBeSold>
  <securitiesClassTitle>Common Stock</securitiesClassTitle>
  <acquiredDate>06/27/2019</acquiredDate>
  <natureOfAcquisitionTransaction>Conversion of Series C Preferred Units in Issuer's IPO</natureOfAcquisitionTransaction>
  <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
  <isGiftTransaction>N</isGiftTransaction>
  <amountOfSecuritiesAcquired>479280</amountOfSecuritiesAcquired>
  <paymentDate>12/15/2017</paymentDate>
  <natureOfPayment>Cash</natureOfPayment>
  </securitiesToBeSold>
  <securitiesToBeSold>
  <securitiesClassTitle>Common Stock</securitiesClassTitle>
  <acquiredDate>06/27/2019</acquiredDate>
  <natureOfAcquisitionTransaction>Conversion of Series C Preferred Units in Issuer's IPO</natureOfAcquisitionTransaction>
  <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
  <isGiftTransaction>N</isGiftTransaction>
  <amountOfSecuritiesAcquired>347956</amountOfSecuritiesAcquired>
  <paymentDate>04/10/2018</paymentDate>
  <natureOfPayment>Cash</natureOfPayment>
  </securitiesToBeSold>
  <securitiesToBeSold>
  <securitiesClassTitle>Common Stock</securitiesClassTitle>
  <acquiredDate>06/27/2019</acquiredDate>
  <natureOfAcquisitionTransaction>Conversion of Series D Preferred Units in Issuer's IPO</natureOfAcquisitionTransaction>
  <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
  <isGiftTransaction>N</isGiftTransaction>
  <amountOfSecuritiesAcquired>1133163</amountOfSecuritiesAcquired>
  <paymentDate>11/20/2018</paymentDate>
  <natureOfPayment>Cash</natureOfPayment>
  </securitiesToBeSold>
  <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
  <remarks>The shares reported herein were sold by the following funds managed by the reporting person: Viking Global Opportunities Illiquid Investments Sub-Master LP, Viking Global Equities Master Ltd. and Viking Long Fund Master Ltd.</remarks>
  <noticeSignature>
  <noticeDate>01/31/2025</noticeDate>
  <signature>/s/ Scott M. Hendler, Authorized Signatory</signature>
  </noticeSignature>
  </formData>
  </edgarSubmission>
metadata_documents: [{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 4726}]
text: 144
  0001103804
  XXXXXXXX
  LIVE
  0001743881
  BridgeBio Pharma, Inc.
  001-38959
  3160 Porter Drive
  Suite 250
  Palo Alto
  CA
  94304
  (650) 391-9740
  VIKING GLOBAL INVESTORS LP
  10% Stockholder
  Common Stock
  Citigroup
  388 Greenwich Street
  New York
  NY
  10013
  3065616
  106989998.4
  188989802
  01/31/2025
  NASDAQ
  Common Stock
  06/27/2019
  Purchases in Issuer's IPO
  Underwriter
  N
  625937
  07/01/2019
  Cash
  Common Stock
  06/27/2019
  Conversion of Series C Preferred Units in Issuer's IPO
  Issuer
  N
  479280
  08/15/2017
  Cash
  Common Stock
  06/27/2019
  Conversion of Series C Preferred Units in Issuer's IPO
  Issuer
  N
  479280
  12/15/2017
  Cash
  Common Stock
  06/27/2019
  Conversion of Series C Preferred Units in Issuer's IPO
  Issuer
  N
  347956
  04/10/2018
  Cash
  Common Stock
  06/27/2019
  Conversion of Series D Preferred Units in Issuer's IPO
  Issuer
  N
  1133163
  11/20/2018
  Cash
  Y
  The shares reported herein were sold by the following funds managed by the reporting person: Viking Global Opportunities Illiquid Investments Sub-Master LP, Viking Global Equities Master Ltd. and Viking Long Fund Master Ltd.
  01/31/2025
  /s/ Scott M. Hendler, Authorized Signatory